Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00959647 · ClinicalTrials.gov registry record · Phase 2
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00959647 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 19 participants.
The verdict
NCT00959647, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.
Interventions
- DRUG Bevacizumab
- DRUG Vismodegib
- DRUG FOLFIRI
- DRUG FOLFOX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-09-03 |
| Est. Completion | 2014-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00959647
The ClinicalTrials.gov registry entry for NCT00959647 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00959647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00959647 about?
NCT00959647 is a clinical study titled "A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study". This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.
What is the current status of trial NCT00959647?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2009-09-03. Estimated completion is 2014-01-09.
What interventions are being tested in trial NCT00959647?
The interventions under investigation include: Bevacizumab (DRUG), Vismodegib (DRUG), FOLFIRI (DRUG), FOLFOX (DRUG).
Who is sponsoring clinical trial NCT00959647?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.